July, 2024
July 2024
Gabriela Burgos: My key takeaways from ASCO 2024
Jun 8, 2024, 06:52

Gabriela Burgos: My key takeaways from ASCO 2024

Gabriela Burgos, Associate Research Director- Evidence Generation Lead, RWE at Oracleย shared a post on LinkedIn:

โ€œAbsolutely invigorated by American Society of Clinical Oncology (ASCO) 2024! Lots of information was shared and insightful client meetings were held.
Here are some key takeaways from my time there:

๐Œ๐š๐ฃ๐จ๐ซ ๐ƒ๐ž๐ฏ๐ž๐ฅ๐จ๐ฉ๐ฆ๐ž๐ง๐ญ๐ฌ:
โ€ข Phase 2/3 Research: Significant progress in various tumors particularly lung and breast cancer, with biomarker-driven therapies leading the way.
โ€ข Cancer Vaccines: Promising future, especially when combined with immunotherapy (IO). Exciting examples include mRNA vaccine with Pembrolizumab for melanoma and neoantigen vaccine with IO for Lynch Syndrome.

๐€๐ˆ ๐ข๐ง ๐Ž๐ง๐œ๐จ๐ฅ๐จ๐ ๐ฒ:
โ€ข AI’s presence is stronger than ever, with applications ranging from identifying patients in Electronic Medical Records (EMRs) and providing medical recommendations to assisting with note writing and administrative tasks. A standout example is MyEleanor, an AI-based virtual patient navigator, which increased patient’s adherence to colorectal screenings in the Bronx, New York. While AI is transformative, continuous quality checks of both inputs and outputs remain crucial.

๐‘Šโ„Ž๐‘–๐‘™๐‘’ ๐‘กโ„Ž๐‘’ ๐‘™๐‘Ž๐‘ก๐‘’๐‘ ๐‘ก ๐‘Ž๐‘›๐‘‘ ๐‘”๐‘Ÿ๐‘’๐‘Ž๐‘ก๐‘’๐‘ ๐‘ก ๐‘‘๐‘’๐‘ฃ๐‘’๐‘™๐‘œ๐‘๐‘š๐‘’๐‘›๐‘ก๐‘ , ๐‘ก๐‘’๐‘โ„Ž, ๐‘Ž๐‘›๐‘‘ ๐‘‘๐‘Ž๐‘ก๐‘Ž ๐‘ค๐‘Ž๐‘  ๐‘Ž โ„Ž๐‘–๐‘”โ„Ž๐‘™๐‘–๐‘”โ„Ž๐‘ก ๐‘œ๐‘“ ๐ด๐‘†๐ถ๐‘‚, ๐’•๐’‰๐’† ๐’‘๐’‚๐’•๐’Š๐’†๐’๐’•’๐’” ๐’—๐’๐’Š๐’„๐’† ๐‘ค๐‘Ž๐‘  ๐‘›๐‘’๐‘’๐‘‘๐‘’๐‘‘ ๐‘Ž๐‘›๐‘‘ ๐‘œ๐‘“ ๐‘–๐‘›๐‘ก๐‘’๐‘Ÿ๐‘’๐‘ ๐‘ก ๐‘ก๐‘œ ๐‘Ž๐‘ก๐‘ก๐‘’๐‘›๐‘‘๐‘’๐‘’๐‘ .

๐Ÿ๐‹ ๐“๐ซ๐ž๐š๐ญ๐ฆ๐ž๐ง๐ญ ๐๐ซ๐ž๐Ÿ๐ž๐ซ๐ž๐ง๐œ๐ž๐ฌ ๐ข๐ง ๐€๐๐ฏ๐š๐ง๐œ๐ž๐ ๐Œ๐ž๐ฅ๐š๐ง๐จ๐ฆ๐š:
โ€ข In collaboration with Bristol Myers Squibb, our study on 1L treatment preferences in advanced melanoma garnered significant interest. Attendees wanted to know the preferences of patients with advanced melanoma and treating oncologists in the current treatment guidelines landscape. Using a discrete choice experiment, findings showed that both patients and oncologists prioritize effective IO regimens while ensuring favorable risk-benefit profiles.

๐‚๐š๐ง๐œ๐ž๐ซ ๐’๐ฎ๐ซ๐ฏ๐ข๐ฏ๐จ๐ซ๐ฌ๐ก๐ข๐ฉ:
โ€ข I attended a community in practice meeting on cancer survivorship. While the panel topic was developing survivorship programs in institutions, the Q&A discussion was enriched by diverse perspectives from oncologists, program directors, cancer survivors, researchers, and patient advocates. The main points that stood out were that survivorship care needs to align with cancer survivors needs and expectations. As we see in our research at Oracle Life Sciences, the patient experience and voice is crucial in survivorship care.ย Also, survivorship care is in the spotlight, not only on a government and institution scale, but also in research. Given the new treatments available such as IO, there is a gap in understanding cancer survivors outcomes longitudinally.

Feeling inspired by the innovations and the commitment to enhancing patient care. Looking forward to the future of oncology!โ€

Gabriela Burgos

Source: Gabriela Burgos/LinkedIn